nodes	percent_of_prediction	percent_of_DWPC	metapath
Cysteamine—MPO—urinary bladder cancer	0.551	1	CbGaD
Cysteamine—MPO—Carboplatin—urinary bladder cancer	0.172	0.539	CbGbCtD
Cysteamine—MPO—Cisplatin—urinary bladder cancer	0.147	0.461	CbGbCtD
Cysteamine—SST—prostate gland—urinary bladder cancer	0.00549	0.213	CbGeAlD
Cysteamine—SST—epithelium—urinary bladder cancer	0.00403	0.157	CbGeAlD
Cysteamine—SST—smooth muscle tissue—urinary bladder cancer	0.00388	0.151	CbGeAlD
Cysteamine—SST—renal system—urinary bladder cancer	0.00374	0.145	CbGeAlD
Cysteamine—SST—female reproductive system—urinary bladder cancer	0.00299	0.116	CbGeAlD
Cysteamine—SST—lymph node—urinary bladder cancer	0.00175	0.0681	CbGeAlD
Cysteamine—MPO—epithelium—urinary bladder cancer	0.00162	0.0631	CbGeAlD
Cysteamine—MPO—renal system—urinary bladder cancer	0.00151	0.0586	CbGeAlD
Cysteamine—SST—Mecp2 and Associated Rett Syndrome—NCOR1—urinary bladder cancer	0.00116	0.0604	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—KMT2A—urinary bladder cancer	0.00111	0.0578	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—PTCRA—urinary bladder cancer	0.00109	0.0568	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—SLC19A1—urinary bladder cancer	0.00103	0.0535	CbGpPWpGaD
Cysteamine—MPO—lymph node—urinary bladder cancer	0.000706	0.0274	CbGeAlD
Cysteamine—SST—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000586	0.0305	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—BIRC3—urinary bladder cancer	0.000552	0.0287	CbGpPWpGaD
Cysteamine—MPO—Vitamin B12 Metabolism—SOD2—urinary bladder cancer	0.000442	0.023	CbGpPWpGaD
Cysteamine—MPO—Vitamin B12 Metabolism—MTHFR—urinary bladder cancer	0.000389	0.0202	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—SOD2—urinary bladder cancer	0.00036	0.0187	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—TYMS—urinary bladder cancer	0.000358	0.0186	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.000354	0.0184	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—GPX1—urinary bladder cancer	0.000343	0.0178	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—FAS—urinary bladder cancer	0.000318	0.0165	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—MTHFR—urinary bladder cancer	0.000317	0.0165	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000312	0.0162	CbGpPWpGaD
Cysteamine—MPO—IL23-mediated signaling events—IL2—urinary bladder cancer	0.000298	0.0155	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—NCOR1—urinary bladder cancer	0.000296	0.0154	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—GSTM1—urinary bladder cancer	0.000296	0.0154	CbGpPWpGaD
Cysteamine—MPO—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000286	0.0149	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000279	0.0145	CbGpPWpGaD
Cysteamine—MPO—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000273	0.0142	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000254	0.0132	CbGpPWpGaD
Cysteamine—MPO—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000252	0.0131	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000247	0.0129	CbGpPWpGaD
Cysteamine—MPO—IL23-mediated signaling events—TNF—urinary bladder cancer	0.000217	0.0113	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000212	0.011	CbGpPWpGaD
Cysteamine—SST—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	0.000211	0.011	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—CREBBP—urinary bladder cancer	0.000204	0.0106	CbGpPWpGaD
Cysteamine—NPY2R—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	0.000203	0.0105	CbGpPWpGaD
Cysteamine—Somnolence—Thiotepa—urinary bladder cancer	0.000198	0.00231	CcSEcCtD
Cysteamine—Anaemia—Cisplatin—urinary bladder cancer	0.000197	0.0023	CcSEcCtD
Cysteamine—Dyspepsia—Thiotepa—urinary bladder cancer	0.000196	0.00228	CcSEcCtD
Cysteamine—Convulsion—Fluorouracil—urinary bladder cancer	0.000195	0.00228	CcSEcCtD
Cysteamine—Blood alkaline phosphatase increased—Doxorubicin—urinary bladder cancer	0.000194	0.00226	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000194	0.00226	CcSEcCtD
Cysteamine—Decreased appetite—Thiotepa—urinary bladder cancer	0.000193	0.00225	CcSEcCtD
Cysteamine—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.000193	0.00225	CcSEcCtD
Cysteamine—Discomfort—Gemcitabine—urinary bladder cancer	0.000193	0.00225	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000192	0.00224	CcSEcCtD
Cysteamine—Fatigue—Thiotepa—urinary bladder cancer	0.000192	0.00224	CcSEcCtD
Cysteamine—Leukopenia—Cisplatin—urinary bladder cancer	0.000191	0.00223	CcSEcCtD
Cysteamine—Constipation—Thiotepa—urinary bladder cancer	0.00019	0.00222	CcSEcCtD
Cysteamine—Discomfort—Fluorouracil—urinary bladder cancer	0.00019	0.00221	CcSEcCtD
Cysteamine—MPO—Folate Metabolism—IL2—urinary bladder cancer	0.000187	0.00974	CbGpPWpGaD
Cysteamine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000187	0.00218	CcSEcCtD
Cysteamine—Eye pain—Doxorubicin—urinary bladder cancer	0.000187	0.00218	CcSEcCtD
Cysteamine—Lethargy—Epirubicin—urinary bladder cancer	0.000186	0.00217	CcSEcCtD
Cysteamine—Confusional state—Fluorouracil—urinary bladder cancer	0.000185	0.00216	CcSEcCtD
Cysteamine—Convulsion—Cisplatin—urinary bladder cancer	0.000185	0.00216	CcSEcCtD
Cysteamine—Mood swings—Methotrexate—urinary bladder cancer	0.000184	0.00215	CcSEcCtD
Cysteamine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000184	0.00214	CcSEcCtD
Cysteamine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000183	0.00214	CcSEcCtD
Cysteamine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000183	0.00214	CcSEcCtD
Cysteamine—Ataxia—Methotrexate—urinary bladder cancer	0.000183	0.00213	CcSEcCtD
Cysteamine—Pain in extremity—Epirubicin—urinary bladder cancer	0.000182	0.00212	CcSEcCtD
Cysteamine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000182	0.00212	CcSEcCtD
Cysteamine—Skin disorder—Gemcitabine—urinary bladder cancer	0.000182	0.00212	CcSEcCtD
Cysteamine—Anaemia—Etoposide—urinary bladder cancer	0.000181	0.00211	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000181	0.00211	CcSEcCtD
Cysteamine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00018	0.0021	CcSEcCtD
Cysteamine—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.00018	0.0021	CcSEcCtD
Cysteamine—Discomfort—Cisplatin—urinary bladder cancer	0.00018	0.0021	CcSEcCtD
Cysteamine—Affect lability—Epirubicin—urinary bladder cancer	0.000179	0.00209	CcSEcCtD
Cysteamine—SST—G alpha (i) signalling events—CXCL8—urinary bladder cancer	0.000178	0.00926	CbGpPWpGaD
Cysteamine—Anorexia—Gemcitabine—urinary bladder cancer	0.000178	0.00208	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	0.000178	0.00926	CbGpPWpGaD
Cysteamine—Urticaria—Thiotepa—urinary bladder cancer	0.000177	0.00206	CcSEcCtD
Cysteamine—Body temperature increased—Thiotepa—urinary bladder cancer	0.000176	0.00205	CcSEcCtD
Cysteamine—Abdominal pain—Thiotepa—urinary bladder cancer	0.000176	0.00205	CcSEcCtD
Cysteamine—Anorexia—Fluorouracil—urinary bladder cancer	0.000175	0.00204	CcSEcCtD
Cysteamine—Leukopenia—Etoposide—urinary bladder cancer	0.000175	0.00204	CcSEcCtD
Cysteamine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000174	0.00203	CcSEcCtD
Cysteamine—NPY2R—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000174	0.00905	CbGpPWpGaD
Cysteamine—Mood swings—Epirubicin—urinary bladder cancer	0.000173	0.00201	CcSEcCtD
Cysteamine—SST—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000172	0.00895	CbGpPWpGaD
Cysteamine—Lethargy—Doxorubicin—urinary bladder cancer	0.000172	0.00201	CcSEcCtD
Cysteamine—Ataxia—Epirubicin—urinary bladder cancer	0.000171	0.002	CcSEcCtD
Cysteamine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000171	0.00199	CcSEcCtD
Cysteamine—NPY2R—G alpha (i) signalling events—CXCL8—urinary bladder cancer	0.000171	0.00888	CbGpPWpGaD
Cysteamine—Convulsion—Etoposide—urinary bladder cancer	0.00017	0.00198	CcSEcCtD
Cysteamine—Dehydration—Epirubicin—urinary bladder cancer	0.000169	0.00198	CcSEcCtD
Cysteamine—Skin disorder—Cisplatin—urinary bladder cancer	0.000169	0.00198	CcSEcCtD
Cysteamine—Hypertension—Etoposide—urinary bladder cancer	0.000169	0.00197	CcSEcCtD
Cysteamine—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000169	0.00197	CcSEcCtD
Cysteamine—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.000168	0.00196	CcSEcCtD
Cysteamine—MPO—Vitamin B12 Metabolism—TNF—urinary bladder cancer	0.000168	0.00872	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—PTGS2—urinary bladder cancer	0.000167	0.00866	CbGpPWpGaD
Cysteamine—Somnolence—Gemcitabine—urinary bladder cancer	0.000166	0.00194	CcSEcCtD
Cysteamine—Anorexia—Cisplatin—urinary bladder cancer	0.000166	0.00194	CcSEcCtD
Cysteamine—NPY2R—Circadian rythm related genes—EP300—urinary bladder cancer	0.000166	0.00863	CbGpPWpGaD
Cysteamine—Affect lability—Doxorubicin—urinary bladder cancer	0.000166	0.00193	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000165	0.00193	CcSEcCtD
Cysteamine—Discomfort—Etoposide—urinary bladder cancer	0.000165	0.00192	CcSEcCtD
Cysteamine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000164	0.00191	CcSEcCtD
Cysteamine—Somnolence—Fluorouracil—urinary bladder cancer	0.000163	0.00191	CcSEcCtD
Cysteamine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000163	0.0019	CcSEcCtD
Cysteamine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000162	0.00189	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000161	0.00188	CcSEcCtD
Cysteamine—Fatigue—Gemcitabine—urinary bladder cancer	0.000161	0.00188	CcSEcCtD
Cysteamine—Confusional state—Etoposide—urinary bladder cancer	0.000161	0.00188	CcSEcCtD
Cysteamine—MPO—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.000161	0.00834	CbGpPWpGaD
Cysteamine—Constipation—Gemcitabine—urinary bladder cancer	0.00016	0.00187	CcSEcCtD
Cysteamine—SST—Signaling Pathways—HDAC4—urinary bladder cancer	0.00016	0.00831	CbGpPWpGaD
Cysteamine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00016	0.00186	CcSEcCtD
Cysteamine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00016	0.00186	CcSEcCtD
Cysteamine—Mood swings—Doxorubicin—urinary bladder cancer	0.00016	0.00186	CcSEcCtD
Cysteamine—Asthenia—Thiotepa—urinary bladder cancer	0.00016	0.00186	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000159	0.00185	CcSEcCtD
Cysteamine—Ataxia—Doxorubicin—urinary bladder cancer	0.000158	0.00185	CcSEcCtD
Cysteamine—Dehydration—Doxorubicin—urinary bladder cancer	0.000157	0.00183	CcSEcCtD
Cysteamine—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000156	0.00181	CcSEcCtD
Cysteamine—Skin disorder—Etoposide—urinary bladder cancer	0.000155	0.00181	CcSEcCtD
Cysteamine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000154	0.0018	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—HDAC4—urinary bladder cancer	0.000153	0.00797	CbGpPWpGaD
Cysteamine—Anorexia—Etoposide—urinary bladder cancer	0.000152	0.00178	CcSEcCtD
Cysteamine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000152	0.00177	CcSEcCtD
Cysteamine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000152	0.00177	CcSEcCtD
Cysteamine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000152	0.00177	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—CCND1—urinary bladder cancer	0.000151	0.00783	CbGpPWpGaD
Cysteamine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000151	0.00176	CcSEcCtD
Cysteamine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000148	0.00172	CcSEcCtD
Cysteamine—Renal failure—Methotrexate—urinary bladder cancer	0.000147	0.00172	CcSEcCtD
Cysteamine—Dizziness—Thiotepa—urinary bladder cancer	0.000147	0.00171	CcSEcCtD
Cysteamine—Urticaria—Fluorouracil—urinary bladder cancer	0.000146	0.0017	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	0.000146	0.00757	CbGpPWpGaD
Cysteamine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000145	0.0017	CcSEcCtD
Cysteamine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000144	0.00168	CcSEcCtD
Cysteamine—Somnolence—Etoposide—urinary bladder cancer	0.000142	0.00166	CcSEcCtD
Cysteamine—SST—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000142	0.00737	CbGpPWpGaD
Cysteamine—Vomiting—Thiotepa—urinary bladder cancer	0.000141	0.00165	CcSEcCtD
Cysteamine—Rash—Thiotepa—urinary bladder cancer	0.00014	0.00164	CcSEcCtD
Cysteamine—Dermatitis—Thiotepa—urinary bladder cancer	0.00014	0.00163	CcSEcCtD
Cysteamine—Headache—Thiotepa—urinary bladder cancer	0.000139	0.00162	CcSEcCtD
Cysteamine—Decreased appetite—Etoposide—urinary bladder cancer	0.000139	0.00162	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—EP300—urinary bladder cancer	0.000139	0.0072	CbGpPWpGaD
Cysteamine—Renal failure—Epirubicin—urinary bladder cancer	0.000138	0.00161	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000138	0.00161	CcSEcCtD
Cysteamine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000138	0.00161	CcSEcCtD
Cysteamine—Fatigue—Etoposide—urinary bladder cancer	0.000138	0.00161	CcSEcCtD
Cysteamine—Constipation—Etoposide—urinary bladder cancer	0.000137	0.00159	CcSEcCtD
Cysteamine—MPO—Folate Metabolism—TNF—urinary bladder cancer	0.000136	0.00709	CbGpPWpGaD
Cysteamine—NPY2R—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000136	0.00706	CbGpPWpGaD
Cysteamine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000135	0.00158	CcSEcCtD
Cysteamine—Asthenia—Gemcitabine—urinary bladder cancer	0.000134	0.00157	CcSEcCtD
Cysteamine—SST—Signaling Pathways—GLI1—urinary bladder cancer	0.000134	0.00696	CbGpPWpGaD
Cysteamine—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000133	0.00155	CcSEcCtD
Cysteamine—Nausea—Thiotepa—urinary bladder cancer	0.000132	0.00154	CcSEcCtD
Cysteamine—Urethral disorder—Methotrexate—urinary bladder cancer	0.000132	0.00154	CcSEcCtD
Cysteamine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000132	0.00154	CcSEcCtD
Cysteamine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000131	0.00152	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—GLI1—urinary bladder cancer	0.000128	0.00668	CbGpPWpGaD
Cysteamine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000128	0.0015	CcSEcCtD
Cysteamine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000128	0.00149	CcSEcCtD
Cysteamine—Renal failure—Doxorubicin—urinary bladder cancer	0.000128	0.00149	CcSEcCtD
Cysteamine—Urticaria—Etoposide—urinary bladder cancer	0.000127	0.00148	CcSEcCtD
Cysteamine—Body temperature increased—Etoposide—urinary bladder cancer	0.000126	0.00147	CcSEcCtD
Cysteamine—Abdominal pain—Etoposide—urinary bladder cancer	0.000126	0.00147	CcSEcCtD
Cysteamine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000126	0.00147	CcSEcCtD
Cysteamine—Asthenia—Cisplatin—urinary bladder cancer	0.000125	0.00146	CcSEcCtD
Cysteamine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000124	0.00145	CcSEcCtD
Cysteamine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000124	0.00144	CcSEcCtD
Cysteamine—Urethral disorder—Epirubicin—urinary bladder cancer	0.000124	0.00144	CcSEcCtD
Cysteamine—Immune system disorder—Methotrexate—urinary bladder cancer	0.000122	0.00142	CcSEcCtD
Cysteamine—Dizziness—Fluorouracil—urinary bladder cancer	0.000122	0.00142	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—MYC—urinary bladder cancer	0.000121	0.00628	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—TP53—urinary bladder cancer	0.00012	0.00625	CbGpPWpGaD
Cysteamine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000119	0.00139	CcSEcCtD
Cysteamine—Vomiting—Gemcitabine—urinary bladder cancer	0.000119	0.00139	CcSEcCtD
Cysteamine—NPY2R—Circadian rythm related genes—TP53—urinary bladder cancer	0.000119	0.00618	CbGpPWpGaD
Cysteamine—Mental disorder—Methotrexate—urinary bladder cancer	0.000118	0.00138	CcSEcCtD
Cysteamine—Rash—Gemcitabine—urinary bladder cancer	0.000118	0.00138	CcSEcCtD
Cysteamine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000118	0.00137	CcSEcCtD
Cysteamine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000118	0.00137	CcSEcCtD
Cysteamine—Malnutrition—Methotrexate—urinary bladder cancer	0.000117	0.00137	CcSEcCtD
Cysteamine—Erythema—Methotrexate—urinary bladder cancer	0.000117	0.00137	CcSEcCtD
Cysteamine—Headache—Gemcitabine—urinary bladder cancer	0.000117	0.00137	CcSEcCtD
Cysteamine—Vomiting—Fluorouracil—urinary bladder cancer	0.000117	0.00136	CcSEcCtD
Cysteamine—Rash—Fluorouracil—urinary bladder cancer	0.000116	0.00135	CcSEcCtD
Cysteamine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000116	0.00135	CcSEcCtD
Cysteamine—Headache—Fluorouracil—urinary bladder cancer	0.000115	0.00134	CcSEcCtD
Cysteamine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000115	0.00134	CcSEcCtD
Cysteamine—Asthenia—Etoposide—urinary bladder cancer	0.000115	0.00134	CcSEcCtD
Cysteamine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000115	0.00134	CcSEcCtD
Cysteamine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000114	0.00133	CcSEcCtD
Cysteamine—Immune system disorder—Epirubicin—urinary bladder cancer	0.000114	0.00133	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—KRAS—urinary bladder cancer	0.000112	0.0058	CbGpPWpGaD
Cysteamine—Nausea—Gemcitabine—urinary bladder cancer	0.000111	0.0013	CcSEcCtD
Cysteamine—Vomiting—Cisplatin—urinary bladder cancer	0.000111	0.00129	CcSEcCtD
Cysteamine—Mental disorder—Epirubicin—urinary bladder cancer	0.00011	0.00129	CcSEcCtD
Cysteamine—Rash—Cisplatin—urinary bladder cancer	0.00011	0.00128	CcSEcCtD
Cysteamine—Dermatitis—Cisplatin—urinary bladder cancer	0.00011	0.00128	CcSEcCtD
Cysteamine—Malnutrition—Epirubicin—urinary bladder cancer	0.00011	0.00128	CcSEcCtD
Cysteamine—Erythema—Epirubicin—urinary bladder cancer	0.00011	0.00128	CcSEcCtD
Cysteamine—Diarrhoea—Etoposide—urinary bladder cancer	0.000109	0.00127	CcSEcCtD
Cysteamine—Nausea—Fluorouracil—urinary bladder cancer	0.000109	0.00127	CcSEcCtD
Cysteamine—MPO—Selenium Micronutrient Network—TNF—urinary bladder cancer	0.000108	0.00563	CbGpPWpGaD
Cysteamine—Anaemia—Methotrexate—urinary bladder cancer	0.000108	0.00126	CcSEcCtD
Cysteamine—SST—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000108	0.00561	CbGpPWpGaD
Cysteamine—Tension—Epirubicin—urinary bladder cancer	0.000108	0.00126	CcSEcCtD
Cysteamine—Nervousness—Epirubicin—urinary bladder cancer	0.000107	0.00124	CcSEcCtD
Cysteamine—Dizziness—Etoposide—urinary bladder cancer	0.000106	0.00123	CcSEcCtD
Cysteamine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000105	0.00123	CcSEcCtD
Cysteamine—Leukopenia—Methotrexate—urinary bladder cancer	0.000105	0.00122	CcSEcCtD
Cysteamine—Nausea—Cisplatin—urinary bladder cancer	0.000104	0.00121	CcSEcCtD
Cysteamine—NPY2R—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000103	0.00538	CbGpPWpGaD
Cysteamine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000102	0.00119	CcSEcCtD
Cysteamine—Convulsion—Methotrexate—urinary bladder cancer	0.000102	0.00118	CcSEcCtD
Cysteamine—Vomiting—Etoposide—urinary bladder cancer	0.000102	0.00118	CcSEcCtD
Cysteamine—Erythema—Doxorubicin—urinary bladder cancer	0.000101	0.00118	CcSEcCtD
Cysteamine—Malnutrition—Doxorubicin—urinary bladder cancer	0.000101	0.00118	CcSEcCtD
Cysteamine—Anaemia—Epirubicin—urinary bladder cancer	0.000101	0.00118	CcSEcCtD
Cysteamine—Agitation—Epirubicin—urinary bladder cancer	0.000101	0.00118	CcSEcCtD
Cysteamine—Rash—Etoposide—urinary bladder cancer	0.000101	0.00117	CcSEcCtD
Cysteamine—Dermatitis—Etoposide—urinary bladder cancer	0.000101	0.00117	CcSEcCtD
Cysteamine—Headache—Etoposide—urinary bladder cancer	0.0001	0.00117	CcSEcCtD
Cysteamine—Tension—Doxorubicin—urinary bladder cancer	9.96e-05	0.00116	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	9.91e-05	0.00116	CcSEcCtD
Cysteamine—Discomfort—Methotrexate—urinary bladder cancer	9.86e-05	0.00115	CcSEcCtD
Cysteamine—Nervousness—Doxorubicin—urinary bladder cancer	9.86e-05	0.00115	CcSEcCtD
Cysteamine—Leukopenia—Epirubicin—urinary bladder cancer	9.82e-05	0.00115	CcSEcCtD
Cysteamine—Confusional state—Methotrexate—urinary bladder cancer	9.65e-05	0.00113	CcSEcCtD
Cysteamine—Anaphylactic shock—Methotrexate—urinary bladder cancer	9.57e-05	0.00112	CcSEcCtD
Cysteamine—Convulsion—Epirubicin—urinary bladder cancer	9.5e-05	0.00111	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—HRAS—urinary bladder cancer	9.49e-05	0.00493	CbGpPWpGaD
Cysteamine—Nausea—Etoposide—urinary bladder cancer	9.49e-05	0.00111	CcSEcCtD
Cysteamine—Hypertension—Epirubicin—urinary bladder cancer	9.47e-05	0.0011	CcSEcCtD
Cysteamine—Nervous system disorder—Methotrexate—urinary bladder cancer	9.38e-05	0.00109	CcSEcCtD
Cysteamine—Anaemia—Doxorubicin—urinary bladder cancer	9.38e-05	0.00109	CcSEcCtD
Cysteamine—Agitation—Doxorubicin—urinary bladder cancer	9.33e-05	0.00109	CcSEcCtD
Cysteamine—Skin disorder—Methotrexate—urinary bladder cancer	9.29e-05	0.00108	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	9.27e-05	0.00108	CcSEcCtD
Cysteamine—Discomfort—Epirubicin—urinary bladder cancer	9.23e-05	0.00108	CcSEcCtD
Cysteamine—SST—Signaling Pathways—RBX1—urinary bladder cancer	9.18e-05	0.00477	CbGpPWpGaD
Cysteamine—Anorexia—Methotrexate—urinary bladder cancer	9.12e-05	0.00106	CcSEcCtD
Cysteamine—Leukopenia—Doxorubicin—urinary bladder cancer	9.09e-05	0.00106	CcSEcCtD
Cysteamine—Confusional state—Epirubicin—urinary bladder cancer	9.03e-05	0.00105	CcSEcCtD
Cysteamine—Anaphylactic shock—Epirubicin—urinary bladder cancer	8.95e-05	0.00104	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—RBX1—urinary bladder cancer	8.81e-05	0.00458	CbGpPWpGaD
Cysteamine—Convulsion—Doxorubicin—urinary bladder cancer	8.79e-05	0.00103	CcSEcCtD
Cysteamine—Nervous system disorder—Epirubicin—urinary bladder cancer	8.78e-05	0.00102	CcSEcCtD
Cysteamine—Hypertension—Doxorubicin—urinary bladder cancer	8.76e-05	0.00102	CcSEcCtD
Cysteamine—Skin disorder—Epirubicin—urinary bladder cancer	8.7e-05	0.00101	CcSEcCtD
Cysteamine—SST—Signaling Pathways—TSC1—urinary bladder cancer	8.63e-05	0.00449	CbGpPWpGaD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	8.58e-05	0.001	CcSEcCtD
Cysteamine—Discomfort—Doxorubicin—urinary bladder cancer	8.54e-05	0.000996	CcSEcCtD
Cysteamine—Anorexia—Epirubicin—urinary bladder cancer	8.53e-05	0.000995	CcSEcCtD
Cysteamine—Somnolence—Methotrexate—urinary bladder cancer	8.5e-05	0.000992	CcSEcCtD
Cysteamine—Dyspepsia—Methotrexate—urinary bladder cancer	8.42e-05	0.000982	CcSEcCtD
Cysteamine—Confusional state—Doxorubicin—urinary bladder cancer	8.35e-05	0.000974	CcSEcCtD
Cysteamine—Decreased appetite—Methotrexate—urinary bladder cancer	8.32e-05	0.00097	CcSEcCtD
Cysteamine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	8.28e-05	0.000966	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—TSC1—urinary bladder cancer	8.28e-05	0.0043	CbGpPWpGaD
Cysteamine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	8.26e-05	0.000963	CcSEcCtD
Cysteamine—Fatigue—Methotrexate—urinary bladder cancer	8.25e-05	0.000962	CcSEcCtD
Cysteamine—SST—Signaling Pathways—JAG1—urinary bladder cancer	8.22e-05	0.00427	CbGpPWpGaD
Cysteamine—Nervous system disorder—Doxorubicin—urinary bladder cancer	8.12e-05	0.000948	CcSEcCtD
Cysteamine—Skin disorder—Doxorubicin—urinary bladder cancer	8.05e-05	0.000939	CcSEcCtD
Cysteamine—Somnolence—Epirubicin—urinary bladder cancer	7.96e-05	0.000928	CcSEcCtD
Cysteamine—Anorexia—Doxorubicin—urinary bladder cancer	7.9e-05	0.000921	CcSEcCtD
Cysteamine—Feeling abnormal—Methotrexate—urinary bladder cancer	7.88e-05	0.00092	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—JAG1—urinary bladder cancer	7.88e-05	0.0041	CbGpPWpGaD
Cysteamine—Dyspepsia—Epirubicin—urinary bladder cancer	7.88e-05	0.000919	CcSEcCtD
Cysteamine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	7.82e-05	0.000912	CcSEcCtD
Cysteamine—Decreased appetite—Epirubicin—urinary bladder cancer	7.78e-05	0.000908	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	7.73e-05	0.000902	CcSEcCtD
Cysteamine—Fatigue—Epirubicin—urinary bladder cancer	7.72e-05	0.0009	CcSEcCtD
Cysteamine—Constipation—Epirubicin—urinary bladder cancer	7.66e-05	0.000893	CcSEcCtD
Cysteamine—Urticaria—Methotrexate—urinary bladder cancer	7.6e-05	0.000886	CcSEcCtD
Cysteamine—Abdominal pain—Methotrexate—urinary bladder cancer	7.56e-05	0.000882	CcSEcCtD
Cysteamine—Body temperature increased—Methotrexate—urinary bladder cancer	7.56e-05	0.000882	CcSEcCtD
Cysteamine—Feeling abnormal—Epirubicin—urinary bladder cancer	7.38e-05	0.000861	CcSEcCtD
Cysteamine—Somnolence—Doxorubicin—urinary bladder cancer	7.36e-05	0.000859	CcSEcCtD
Cysteamine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	7.32e-05	0.000854	CcSEcCtD
Cysteamine—Dyspepsia—Doxorubicin—urinary bladder cancer	7.29e-05	0.000851	CcSEcCtD
Cysteamine—Decreased appetite—Doxorubicin—urinary bladder cancer	7.2e-05	0.00084	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	7.15e-05	0.000834	CcSEcCtD
Cysteamine—Fatigue—Doxorubicin—urinary bladder cancer	7.14e-05	0.000833	CcSEcCtD
Cysteamine—Urticaria—Epirubicin—urinary bladder cancer	7.11e-05	0.00083	CcSEcCtD
Cysteamine—Constipation—Doxorubicin—urinary bladder cancer	7.08e-05	0.000826	CcSEcCtD
Cysteamine—Abdominal pain—Epirubicin—urinary bladder cancer	7.08e-05	0.000825	CcSEcCtD
Cysteamine—Body temperature increased—Epirubicin—urinary bladder cancer	7.08e-05	0.000825	CcSEcCtD
Cysteamine—Hypersensitivity—Methotrexate—urinary bladder cancer	7.05e-05	0.000822	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—RHOA—urinary bladder cancer	6.95e-05	0.00361	CbGpPWpGaD
Cysteamine—Asthenia—Methotrexate—urinary bladder cancer	6.86e-05	0.000801	CcSEcCtD
Cysteamine—Feeling abnormal—Doxorubicin—urinary bladder cancer	6.83e-05	0.000796	CcSEcCtD
Cysteamine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	6.77e-05	0.00079	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—RHOA—urinary bladder cancer	6.66e-05	0.00346	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—S100B—urinary bladder cancer	6.66e-05	0.00346	CbGpPWpGaD
Cysteamine—Hypersensitivity—Epirubicin—urinary bladder cancer	6.6e-05	0.000769	CcSEcCtD
Cysteamine—Urticaria—Doxorubicin—urinary bladder cancer	6.58e-05	0.000768	CcSEcCtD
Cysteamine—Abdominal pain—Doxorubicin—urinary bladder cancer	6.55e-05	0.000764	CcSEcCtD
Cysteamine—Body temperature increased—Doxorubicin—urinary bladder cancer	6.55e-05	0.000764	CcSEcCtD
Cysteamine—Diarrhoea—Methotrexate—urinary bladder cancer	6.55e-05	0.000763	CcSEcCtD
Cysteamine—Asthenia—Epirubicin—urinary bladder cancer	6.42e-05	0.000749	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—S100B—urinary bladder cancer	6.38e-05	0.00332	CbGpPWpGaD
Cysteamine—Dizziness—Methotrexate—urinary bladder cancer	6.33e-05	0.000738	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—RHOA—urinary bladder cancer	6.31e-05	0.00328	CbGpPWpGaD
Cysteamine—Diarrhoea—Epirubicin—urinary bladder cancer	6.13e-05	0.000714	CcSEcCtD
Cysteamine—Hypersensitivity—Doxorubicin—urinary bladder cancer	6.1e-05	0.000712	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—CXCL8—urinary bladder cancer	6.1e-05	0.00317	CbGpPWpGaD
Cysteamine—Vomiting—Methotrexate—urinary bladder cancer	6.08e-05	0.000709	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—RHOA—urinary bladder cancer	6.05e-05	0.00314	CbGpPWpGaD
Cysteamine—Rash—Methotrexate—urinary bladder cancer	6.03e-05	0.000704	CcSEcCtD
Cysteamine—Dermatitis—Methotrexate—urinary bladder cancer	6.03e-05	0.000703	CcSEcCtD
Cysteamine—Headache—Methotrexate—urinary bladder cancer	5.99e-05	0.000699	CcSEcCtD
Cysteamine—SST—Signaling Pathways—NCOR1—urinary bladder cancer	5.99e-05	0.00311	CbGpPWpGaD
Cysteamine—Asthenia—Doxorubicin—urinary bladder cancer	5.94e-05	0.000693	CcSEcCtD
Cysteamine—Dizziness—Epirubicin—urinary bladder cancer	5.92e-05	0.000691	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.85e-05	0.00304	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—IL2—urinary bladder cancer	5.83e-05	0.00303	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—NCOR1—urinary bladder cancer	5.74e-05	0.00298	CbGpPWpGaD
Cysteamine—Vomiting—Epirubicin—urinary bladder cancer	5.69e-05	0.000664	CcSEcCtD
Cysteamine—Nausea—Methotrexate—urinary bladder cancer	5.68e-05	0.000663	CcSEcCtD
Cysteamine—Diarrhoea—Doxorubicin—urinary bladder cancer	5.67e-05	0.000661	CcSEcCtD
Cysteamine—Rash—Epirubicin—urinary bladder cancer	5.64e-05	0.000658	CcSEcCtD
Cysteamine—Dermatitis—Epirubicin—urinary bladder cancer	5.64e-05	0.000658	CcSEcCtD
Cysteamine—Headache—Epirubicin—urinary bladder cancer	5.61e-05	0.000654	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—IL2—urinary bladder cancer	5.59e-05	0.0029	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—CXCL8—urinary bladder cancer	5.54e-05	0.00288	CbGpPWpGaD
Cysteamine—Dizziness—Doxorubicin—urinary bladder cancer	5.48e-05	0.000639	CcSEcCtD
Cysteamine—Nausea—Epirubicin—urinary bladder cancer	5.32e-05	0.00062	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—CXCL8—urinary bladder cancer	5.31e-05	0.00276	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—IL2—urinary bladder cancer	5.29e-05	0.00275	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TERT—urinary bladder cancer	5.27e-05	0.00274	CbGpPWpGaD
Cysteamine—Vomiting—Doxorubicin—urinary bladder cancer	5.27e-05	0.000614	CcSEcCtD
Cysteamine—Rash—Doxorubicin—urinary bladder cancer	5.22e-05	0.000609	CcSEcCtD
Cysteamine—Dermatitis—Doxorubicin—urinary bladder cancer	5.22e-05	0.000609	CcSEcCtD
Cysteamine—Headache—Doxorubicin—urinary bladder cancer	5.19e-05	0.000605	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—IL2—urinary bladder cancer	5.08e-05	0.00264	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—TERT—urinary bladder cancer	5.06e-05	0.00263	CbGpPWpGaD
Cysteamine—Nausea—Doxorubicin—urinary bladder cancer	4.92e-05	0.000574	CcSEcCtD
Cysteamine—SST—Signaling Pathways—FGFR3—urinary bladder cancer	4.84e-05	0.00252	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—ESR1—urinary bladder cancer	4.7e-05	0.00244	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—FGFR3—urinary bladder cancer	4.64e-05	0.00241	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—ESR1—urinary bladder cancer	4.51e-05	0.00234	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CREBBP—urinary bladder cancer	4.12e-05	0.00214	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—IGF1—urinary bladder cancer	4.07e-05	0.00211	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—EGFR—urinary bladder cancer	4.05e-05	0.0021	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CREBBP—urinary bladder cancer	3.95e-05	0.00205	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—IGF1—urinary bladder cancer	3.9e-05	0.00203	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—EGFR—urinary bladder cancer	3.88e-05	0.00202	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—KRAS—urinary bladder cancer	3.83e-05	0.00199	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—RHOA—urinary bladder cancer	3.73e-05	0.00194	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—KRAS—urinary bladder cancer	3.67e-05	0.00191	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—RHOA—urinary bladder cancer	3.57e-05	0.00186	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—ERBB2—urinary bladder cancer	3.45e-05	0.00179	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—ERBB2—urinary bladder cancer	3.31e-05	0.00172	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CXCL8—urinary bladder cancer	3.27e-05	0.0017	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—HRAS—urinary bladder cancer	3.25e-05	0.00169	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CXCL8—urinary bladder cancer	3.14e-05	0.00163	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—IL2—urinary bladder cancer	3.13e-05	0.00163	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—HRAS—urinary bladder cancer	3.12e-05	0.00162	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CCND1—urinary bladder cancer	3.05e-05	0.00158	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—IL2—urinary bladder cancer	3e-05	0.00156	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—MMP9—urinary bladder cancer	2.96e-05	0.00154	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CDKN1A—urinary bladder cancer	2.95e-05	0.00153	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PTEN—urinary bladder cancer	2.94e-05	0.00153	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CCND1—urinary bladder cancer	2.92e-05	0.00152	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—MMP9—urinary bladder cancer	2.84e-05	0.00147	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CDKN1A—urinary bladder cancer	2.83e-05	0.00147	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PTEN—urinary bladder cancer	2.82e-05	0.00147	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—EP300—urinary bladder cancer	2.81e-05	0.00146	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—SRC—urinary bladder cancer	2.73e-05	0.00142	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—EP300—urinary bladder cancer	2.69e-05	0.0014	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—SRC—urinary bladder cancer	2.62e-05	0.00136	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—MYC—urinary bladder cancer	2.45e-05	0.00127	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—EGFR—urinary bladder cancer	2.39e-05	0.00124	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—MYC—urinary bladder cancer	2.34e-05	0.00122	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—EGFR—urinary bladder cancer	2.29e-05	0.00119	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—KRAS—urinary bladder cancer	2.26e-05	0.00117	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—KRAS—urinary bladder cancer	2.17e-05	0.00113	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TP53—urinary bladder cancer	2.01e-05	0.00104	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—TP53—urinary bladder cancer	1.93e-05	0.001	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—HRAS—urinary bladder cancer	1.92e-05	0.000998	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—HRAS—urinary bladder cancer	1.84e-05	0.000957	CbGpPWpGaD
